Enteric-Coated Formulation Pellets (Sustained Release)

In advanced solid-dose manufacturing, achieving a precise, time-dependent release of an active pharmaceutical ingredient (API) is crucial for therapeutic success and patient safety. Enteric-Coated Formulation Pellets represent a specialized multi-particulate drug delivery system engineered to bypass the highly acidic environment of the stomach, releasing the medication uniformly within the neutral-to-alkaline environment of the upper small intestine.

The Architecture of Multi-Particulate Pellets

Unlike traditional single-unit tablets, enteric-coated pellets consist of thousands of microscopic, spherical cores enclosed within a hard gelatin or HPMC capsule shell. This formulation utilizes a multi-layered coating technology:

• Inert Core: A uniform spherical seed (often made of microcrystalline cellulose or sugar spheres) that acts as the physical foundation.
• API Layer: The active medication is uniformly layered around the core using highly controlled fluid-bed processing to ensure strict dose uniformity.
• Enteric Barrier Layer: A specialized, pH-sensitive polymer coating (such as Methacrylic Acid Copolymers medkinglifescience.com or Cellulose Acetate Phthalate) is applied as the outermost shield. This polymer remains completely insoluble at a low gastric pH (pH 1.0–3.0) but dissolves rapidly as the pH rises to 5.5 and above in the duodenum.

Key Operational Advantages

Transitioning from standard powders to enteric pellets offers significant manufacturing and clinical benefits:

1. Gastric Mucosal Protection: Prevents direct contact between stomach tissue and chemically aggressive, ulcer-inducing APIs (such as specific NSAIDs or iron salts), drastically lowering the risk of gastric irritation.
2. API Stability: Shields acid-labile drugs—most notably proton-pump inhibitors like Pantoprazole, Omeprazole, and Rabeprazole—from rapid chemical degradation by stomach acids before they can be absorbed.
3. Predictable Pharmacokinetics: Multi-particulate pellets pass through the pyloric sphincter gradually and uniformly. This avoids the sudden “dose dumping” or variable gastric emptying times common with large single tablets, resulting in smooth, predictable drug absorption curves.

Industrial Applications and Bulk Supply

Item 31 is produced as a high-density, free-flowing bulk intermediate designed for automated, high-speed capsule filling lines.

Optimized Flowability: The spherical geometry ensures strict weight uniformity during high-speed encapsulation.

Cross-Division Compatibility: These bulk pellets are distributed across Medking’s primary therapeutic labels (including Addwell Pharma and Symonic Lifescience) to formulate standard-release and dual-action sustained-release (SR/EC) capsule formulations.